Skip to main content
SpringerLink
Log in

HER2-positive breast cancer: neoadjuvant and adjuvant therapy

  • Chapter
  • First Online:
Handbook of HER2-Targeted Agents in Breast Cancer

  • 599 Accesses

Abstract

In principle, anti-human epidermal growth factor receptor 2 (HER2) therapy can be started together with chemotherapy in the adjuvant and neoadjuvant settings. After neoadjuvant chemotherapy in combination with anti-HER2 therapy, trastuzumab is continued for a total of one year in the adjuvant setting. Trastuzumab is the only anti-HER2 agent approved for both the neoadjuvant and adjuvant setting. For neoadjuvant therapy, dual anti-HER2 blockade with trastuzumab and pertuzumab has recently been approved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab vs. neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-384.

    Google Scholar 

  2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.

    Google Scholar 

  3. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351-3357.

    Google Scholar 

  4. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28:2024-2031.

    Google Scholar 

  5. von Minckwitz G, Untch M, Nuesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145-156.

    Google Scholar 

  6. Untch M, Loibl S, Bischoff J, et al; for the German Breast Group (GBG); Arbeitsgemeinschaft Gynakologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135-144.

    Google Scholar 

  7. Baselga J, Bradbury I, Eidtmann H, et al; for the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633-640.

    Google Scholar 

  8. de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15:1137-1146.

    Google Scholar 

  9. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.

    Google Scholar 

  10. Gianni L, Pienkowski T, Im YH, et al. Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). J Clin Oncol. 2015; 33(suppl). Abstr 505.

    Google Scholar 

  11. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278-2284.

    Google Scholar 

  12. Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015;26:320-325.

    Google Scholar 

  13. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.

    Google Scholar 

  14. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6:e21030.

    Google Scholar 

  15. Metzger-Filho O, Procter M, de Azambuja E, et al. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol. 2013;31:1954-1960.

    Google Scholar 

  16. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29:e458.

    Google Scholar 

  17. Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012;104:159-162.

    Google Scholar 

  18. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009;27:2962-2969.

    Google Scholar 

  19. Leyland-Jones B. Dose scheduling–Herceptin. Oncology. 2001;61(suppl 2):31-36.

    Google Scholar 

  20. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869-878.

    Google Scholar 

  21. Gianni L, Dafni U, Gelber RD, et al; for the Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236-244.

    Google Scholar 

  22. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-3373.

    Google Scholar 

  23. Slamon D, Eiermann W, Robert N, et al; for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283.

    Google Scholar 

  24. Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29:4491-4497.

    Google Scholar 

  25. Buzdar AU, Suman VJ, Meric-Bernstam F, et al; American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1317-1325.

    Google Scholar 

  26. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27:6129-6134.

    Google Scholar 

  27. Arbeitsgemeinschaft Gynaekologische Onkologie (AGO). Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. AGO Kommission Mamma. 2015. www.ago-online.de. Accessed November 3, 2015.

  28. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology. Breast Cancer. NCCN Website. 2015. www.nccn.org. Accessed November 3, 2015.

  29. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134-114.

    Google Scholar 

  30. Belkacemi Y, Gligorov J, Ozsahin M, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol. 2008;19:1110-1116.

    Google Scholar 

  31. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al; for the Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382:1021-1028.

    Google Scholar 

  32. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685-5692.

    Google Scholar 

  33. Pivot X, Romieu G, Debled M, Pet al; for the PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741-748.

    Google Scholar 

  34. Untch M, Gelber RD, Jackisch C, et al; for the HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008;19:1090-1096.

    Google Scholar 

  35. Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011;22:2387-2393.

    Google Scholar 

  36. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27:5700-5706.

    Google Scholar 

  37. Rodrigues MJ, Albiges-Sauvin L, Wassermann J, Cottu PH. Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas. Ann Oncol. 2011;22:2530.

    Google Scholar 

  38. Horio A, Fujita T, Hayashi H, et al. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol. 2012;17:131-136.

    Google Scholar 

  39. McArthur HL, Mahoney KM, Morris PG, et al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 2011;117:5461-5468.

    Google Scholar 

  40. Kolben T, Harbeck N, Wuerstlein R,et al. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. Breast. 2015;24:24-31.

    Google Scholar 

  41. Mackey JR, Clemons M, Cote MA, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15:24-35.

    Google Scholar 

  42. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with nodepositive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792-3799.

    Google Scholar 

  43. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumabrelated cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422-3428.

    Google Scholar 

  44. Burstein HJ, Piccart-Gebhart MJ, Perez EA, et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012;30:2179-2182.

    Google Scholar 

  45. Goss PE, Smith IE, O’Shaughnessy J, et al; for the TEACH investigators. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:88-96.

    Google Scholar 

  46. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early HER2-positive breast cancer – results from the randomized phase III ALTTO trial. J C lin Oncol. 2015; In Press.

    Google Scholar 

  47. Chan A, Delaloge S, Holmes FA, et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). J Clin Oncol. 2015;33 (suppl). Abstr 508.

    Google Scholar 

  48. Pivot X, Gligorov J, Muller V, et al; for the PrefHer Study Group. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25:1979-1987.

    Google Scholar 

  49. Food and Drug Administration (FDA). Guidance for Industry Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. May 2012. FDA website. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf. Accessed November 3, 2015.

  50. Swain SM, Baselga J, Kim SB, et al; for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734.

    Google Scholar 

  51. Harbeck N. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: therapeutic implications. Breast. 2015; In Press.

    Google Scholar 

  52. Harbeck N, Gluz O, Christgen M, et al. Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial. J Clin Oncol. 2015;33(suppl). Abstr 506.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Center, University of Munich, Munich, Germany

    Nadia Harbeck

Authors
  1. Nadia Harbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Harbeck, N. (2016). HER2-positive breast cancer: neoadjuvant and adjuvant therapy. In: Handbook of HER2-Targeted Agents in Breast Cancer. Adis, Cham. https://doi.org/10.1007/978-3-319-28216-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28216-9_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-28214-5

  • Online ISBN: 978-3-319-28216-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation